Biography
Dr. Tom Nolin is a tenured Professor in the Department of Pharmacy & Therapeutics, and in the Department of Medicine Renal-Electrolyte Division at the University of Pittsburgh. Dr. Nolin is the Associate Dean for Research and Sponsored Programs, and he is the Director of the University of Pittsburgh Small Molecule Biomarker Core (SMBC) mass spectrometry facility. Visit the SMBC website.Dr. Nolin is an NIH funded investigator whose primary research focuses on developing an understanding of the impact of kidney disease and renal replacement therapy (RRT) on nonrenal metabolism and transport pathways and corresponding effects on drug exposure (pharmacokinetics) and response (pharmacodynamics). Dr. Nolin has a strong record of interdisciplinary and interinstitutional collaborations with regulatory, pharmaceutical industry, and academic scientists in the conduct of clinical-translational studies. He served as chair of the Kidney Health Initiative workgroup to assess pharmacokinetics during RRT and as co-chair of the Extracorporeal Treatments in Poisoning (EXTRIP) Workgroup. Dr. Nolin has published over 200 manuscripts and book chapters and has presented more than 200 scientific abstracts and invited talks. He is an Editor of DiPiro's Pharmacotherapy: A Pathophysiologic Approach textbook. Dr. Nolin is a Fellow of the American College of Clinical Pharmacy, the American College of Clinical Pharmacology, and of the American Society of Nephrology.
Research Interests
The research focus of the Nolin laboratory includes characterizing the impact of kidney disease and renal replacement therapy on drug exposure (clinical pharmacokinetics) and response (pharmacodynamics), evaluating the functional expression of drug metabolizing enzymes and transporters, developing novel quantitative analytical techniques, and assessing the implications of using various kidney function estimating equations on drug eligibility, selection, and dosing. The long-range goal of our research is to identify the mechanisms by which kidney disease contributes to alterations in these drug elimination pathways, to understand the impact of these alterations on drug response and patient outcomes, and ultimately, to use this information in the development of strategies to optimize drug use in patients with kidney disease.In the News
Tom Nolin named Honorary Regent of ACCP
Dr. Tom Nolin was named an Honorary Regent of American College of Clinical Pharmacology (ACCP). He shares: “Being named an...
Congratulations to Dr. Morgan Butrovich on her successful PhD defense!
Congratulations to Dr. Morgan Butrovich on her successful PhD defense! Her work improved our understanding of (1) the impact of...
PittPGx funded to join the NHGRI IGNITE network to recruit for national clinical trial
PittPharmacy’s Pittsburgh Pharmacogenomics group was selected to join the Indiana University Health clinical group to recuit for the NHGRI IGNITE...
Featured Publications
Cardiovascular-kidney-metabolic syndrome in people with HIV: An emerging frontier for clinical pharmacology
Clin Pharmacol Ther. 2025 Dec 10:10.1002/cpt.70164. DOI: 10.1002/cpt.70164. PMID: 41368766.
Pharmacokinetic analysis of morphine-3-glucuronide after acute morphine intravenous bolus administration to rats with traumatic brain injury
J Pharmacol Exp Ther. 2025 Aug;392(8):103645. DOI: 10.1016/j.jpet.2025.103645. PMID: 40729783.
Effect of a population health management intervention on medication therapy problems in people with chronic kidney disease: Post hoc analysis of the K-CHAMP Cluster-Randomized Trial
Kidney Med. 2025 Mar 18;7(5):100995. DOI: 10.1016/j.xkme.2025.100995. PMID: 40330910.
